Stockscreener 앱 받기
3.09
3.44%
-0.11
시간 외 거래:
2.66
-0.43
-13.92%
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
GT Biopharma files automatic mixed securities shelf - MSN
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges - Investing.com
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
New Data Supports BLA Package - Streetwise Reports
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
BeautyHealth Releases 2024 Skintuition Report - Quantisnow
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Nanobodies Market Is Booming Worldwide 2024-2031 | Merck KGaA, - openPR
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
FDA Decision on Drug for Bone Marrow Due Early 2025 - Streetwise Reports
United States Nanobodies Market Size, Trends, Growth, - openPR
Roth Capital Weighs in on GT Biopharma FY2024 Earnings - Defense World
Brokers Set Expectations for GT Biopharma Q4 Earnings - Defense World
Roth Capital Upgrades GT Biopharma (NASDAQ:GTBP) to “Strong-Buy” - Defense World
Is This California Biopharma Co. In the Right Place at the Right Time? - Streetwise Reports
Approval Sought in Japan for New Drug to Lower Cholesterol - Streetwise Reports
Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative - Streetwise Reports
GT Biopharma (NASDAQ:GTBP) Now Covered by Analysts at Roth Mkm - Defense World
Roth/MKM bullish on GT Biopharma stock, sees upside from GTB-3650 revenue potential - Investing.com
Nanobodies Market Future Business Opportunities 2024-2031 | - openPR
GT Biopharma faces Nasdaq delisting over equity shortfall - Investing.com
GT Biopharma faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GT Biopharma (NASDAQ:GTBP) Enters Investigator Initiated Clinical Trial Agreement with the University of Minnesota - Defense World
GT Biopharma inks clinical trial agreement for cancer treatment - Investing.com
GT Biopharma inks clinical trial agreement for cancer treatment By Investing.com - Investing.com UK
GT Metabolic™ Solutions, Inc., announces completion of the first magnetic compression anastomosis cases in the USA following FDA clearance of its linear magnet technologythe MagDI™ System - Yahoo Finance
GT Biopharma Inc. (GTBP) Quarterly 10-Q Report - Quartzy
GT Biopharma Reports Third Quarter 2024 Financial Results - The Manila Times
GT Biopharma Reports $3.4M Q3 Loss, Advances Key Clinical Trial Timeline | GTBP Stock News - StockTitan
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Hydrafacial Announces Glow Getter Scholarship Program in Support of Estheticians - Quantisnow
Nanobodies Market Forecast CAGR 24.1% Projected for Size, Growth, and Share 2024-2031 | Proteintech Group, - EIN News
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
0.50%
1.47%
자본화:
|
볼륨(24시간):